T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production.
CD137
RCC
TIL therapy
dysfunctional T cells
immune composition
immunotherapy
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
21 01 2021
21 01 2021
Historique:
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
29
7
2021
Statut:
epublish
Résumé
Metastatic renal cell carcinoma (RCC) has a poor prognosis. Recent advances have shown beneficial responses to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies. As only a subset of RCC patients respond, alternative strategies should be explored. Patients refractory to anti-PD-1 therapy may benefit from autologous tumor-infiltrating lymphocyte (TIL) therapy. Even though efficient TIL expansion was reported from RCC lesions, it is not well established how many RCC TIL products are tumor-reactive, how well they produce pro-inflammatory cytokines in response to autologous tumors, and whether their response correlates with the presence of specific immune cells in the tumor lesions. We here compared the immune infiltrate composition of RCC lesions with that of autologous kidney tissue of 18 RCC patients. Tcell infiltrates were increased in the tumor lesions, and CD8
Identifiants
pubmed: 33537169
doi: 10.1080/2162402X.2020.1860482
pii: 1860482
pmc: PMC7833735
doi:
Substances chimiques
Interleukin-2
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1860482Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
J Immunother Cancer. 2019 Feb 18;7(1):49
pubmed: 30777131
J Exp Med. 2002 Sep 2;196(5):693-704
pubmed: 12208883
Oncoimmunology. 2019 Aug 15;8(11):e1648170
pubmed: 31646094
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancer Res. 2009 Nov 1;69(21):8412-9
pubmed: 19843860
Cancer Immunol Res. 2019 Nov;7(11):1891-1899
pubmed: 31484656
Clin Cancer Res. 2017 Oct 1;23(19):5779-5788
pubmed: 28679768
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
Cancer Immunol Res. 2018 Feb;6(2):222-235
pubmed: 29301752
Clin Cancer Res. 2016 Aug 1;22(15):3734-45
pubmed: 27006492
J Immunother Cancer. 2017 Oct 17;5(1):82
pubmed: 29041991
N Engl J Med. 2000 Sep 14;343(11):750-8
pubmed: 10984562
Br J Haematol. 2006 Mar;132(6):747-54
pubmed: 16487176
Nat Med. 2005 Oct;11(10):1118-24
pubmed: 16186818
Br J Cancer. 2015 Apr 28;112(9):1510-8
pubmed: 25867267
Clin Cancer Res. 2018 Nov 15;24(22):5562-5573
pubmed: 29853601
Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230
pubmed: 29845338
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Biol Blood Marrow Transplant. 2006 Jul;12(7):778-85
pubmed: 16785067
Oncoimmunology. 2015 Aug 12;5(1):e1067745
pubmed: 26942087
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Hum Vaccin Immunother. 2015;11(12):2790-5
pubmed: 26308285
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Oncoimmunology. 2015 Feb 03;4(1):e985082
pubmed: 25949868
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Clin Oncol. 1999 Aug;17(8):2521-9
pubmed: 10561318
J Immunother Cancer. 2018 Oct 3;6(1):102
pubmed: 30285902
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Clin Cancer Res. 2007 Apr 1;13(7):2075-81
pubmed: 17404089
J Immunol. 1999 Apr 1;162(7):4037-44
pubmed: 10201926
Cancer Immunol Immunother. 2015 Oct;64(10):1241-50
pubmed: 26105626
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753545
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Blood. 2002 Jun 1;99(11):4234-6
pubmed: 12010834
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Anticancer Res. 2009 Jan;29(1):145-54
pubmed: 19331144
Front Oncol. 2019 Oct 25;9:1066
pubmed: 31709176
Oncotarget. 2015 Sep 22;6(28):24990-5002
pubmed: 26317902
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Oncol Lett. 2019 Nov;18(5):5235-5242
pubmed: 31612034
Cancer Immunol Immunother. 2018 Jan;67(1):113-125
pubmed: 28975380
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301
pubmed: 32303540
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
J Adv Res. 2019 Sep 17;21:103-108
pubmed: 32071778
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Clin Cancer Res. 2017 May 15;23(10):2491-2505
pubmed: 27827318
Clin Cancer Res. 2013 Sep 1;19(17):4792-800
pubmed: 23690483
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Tumour Biol. 2015 May;36(5):3727-34
pubmed: 25563193
Bone Marrow Transplant. 2005 Feb;35(3):253-60
pubmed: 15543195
J Clin Oncol. 2005 Jan 1;23(1):133-41
pubmed: 15625368